Table 4.
Combination versus single-agent chemotherapy in platinum-resistant disease
| Study | Agents | Population | PFS | OS |
|---|---|---|---|---|
| Bolis et al28 | Paclitaxel | No benefit | No benefit | |
| Paclitaxel + epirubicin | ||||
| Torri et al29 | Paclitaxel | 50% had resistant disease | No benefit | No benefit |
| Paclitaxel + doxorubicin | ||||
| Buda et al30 | Paclitaxel | 75% had resistant disease | No benefit | No benefit |
| Paclitaxel + epirubicin | ||||
| Sehouli et al31 | Topotecan | No benefit | No benefit | |
| Topotecan + etoposide or gemcitabine | ||||
| Monk et al18 | PLD | No benefit | No benefit | |
| PLD + trabectedin | ||||
| ET43-OVA-301 | weekly paclitaxel | No benefit | No benefit | |
| Lortholary et al32 | weekly paclitaxel + carboplatin or weekly topotecan |
Abbreviations: OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin.